Evaluating the Trade-offs of CAR-T cell Therapy through the correlation of Societal perceptions, Split dosages, and B-cell aplasia

This study evaluates the trade-offs of Chimeric Antigen Receptor (CAR) T-cell therapy by correlating B-cell aplasia under split dosage regimens with the societal perceptions of Taiwanese parents. While CAR-T cell therapy offers significant oncological benefits, its severe toxicities pose substantial physical and psychosocial burdens. Existing literature suggests split dosing mitigates these toxicities, yet its impact on B-cell aplasia and parental perceptions of these trade-offs remains underexplored.

Utilizing a quantitative descriptive approach, this study combined a computational simulation (CARTmath) with a cross-sectional survey of 59 Taiwanese parents. The simulation modeled CAR-T cell expansion and B-cell depletion under single versus fractionated dosages. Simultaneously, the survey assessed parental values regarding treatment risks, benefits, and logistical factors.

Simulation results indicate that split dosing yields a more gradual and controlled depletion of B-cells, hypothetically suggesting that the velocity of depletion may serve as a more reliable clinical marker for treatment efficacy than absolute concentration. Concurrently, survey data revealed an underwhelming awareness for CAR-T therapy among parents, who definitively prioritized safety outcomes—specifically high remission rates and reduced toxicity severity—over logistical concerns like cost or convenience. Furthermore, prolonged toxicities, such as multi-year B-cell aplasia, significantly reduced parental acceptability of the treatment.

Thus, in conclusion, the computational data supporting more plateaued toxicity under split dosages strongly aligns with Taiwanese parents’ prioritization of priority safety, depicting the necessity of integrating and further developing the perspectives of this research paper.